Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

The startup world begins 2025 on a decidedly more upbeat note than it did the previous year. The renewed optimism is in part ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

When we introduced the Nasdaq IPO Pulse a year ago, we said it suggested that U.S. “IPO activity… should remain in an uptrend” as we headed into 2024. Then, when we introduced the Nasdaq ...

Dealmakers see potential for more IPOs next year, but economic headwinds and ample money to stay private could dampen the revival Cloud-computing company CoreWeave Inc. and buy-now-pay-later ...

This story was originally published on PitchBook. The tech IPO market is blocked up by startups that are scared to go public. But if stocks are anything to go by, they have little to fear.

This would be the first bank listing in over 25 years and the country’s first IPO since 2021. The move is a cornerstone of an International Monetary Fund (IMF)-backed privatization program aimed at ...